World Asset Management Inc Has $4.05 Million Holdings in Pfizer Inc. (NYSE:PFE)

World Asset Management Inc reduced its stake in Pfizer Inc. (NYSE:PFE) by 3.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,498 shares of the biopharmaceutical company’s stock after selling 4,071 shares during the period. World Asset Management Inc’s holdings in Pfizer were worth $4,053,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PFE. OLD Mission Capital LLC bought a new stake in shares of Pfizer in the third quarter valued at approximately $291,000. Lehman & Derafelo Financial Resources LLC boosted its stake in shares of Pfizer by 3.6% in the first quarter. Lehman & Derafelo Financial Resources LLC now owns 212,511 shares of the biopharmaceutical company’s stock valued at $7,699,000 after buying an additional 7,354 shares during the period. Ironwood Wealth Management LLC. boosted its stake in shares of Pfizer by 1.6% in the first quarter. Ironwood Wealth Management LLC. now owns 35,385 shares of the biopharmaceutical company’s stock valued at $1,282,000 after buying an additional 550 shares during the period. Petix & Botte Co bought a new stake in shares of Pfizer in the first quarter valued at approximately $187,000. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Pfizer by 14.0% in the first quarter. Los Angeles Capital Management LLC now owns 719,120 shares of the biopharmaceutical company’s stock valued at $26,054,000 after buying an additional 88,403 shares during the period. Institutional investors and hedge funds own 64.93% of the company’s stock.

In related news, SVP Jennifer B. Damico sold 1,661 shares of the business’s stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction dated Friday, July 30th. The stock was sold at an average price of $42.86, for a total transaction of $107,150.00. Following the sale, the senior vice president now directly owns 11,430 shares in the company, valued at approximately $489,889.80. The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.

NYSE PFE traded up $0.18 during trading hours on Wednesday, hitting $44.89. The company’s stock had a trading volume of 487,692 shares, compared to its average volume of 30,836,189. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $251.68 billion, a PE ratio of 19.36, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. Pfizer Inc. has a 52 week low of $33.36 and a 52 week high of $51.86. The company’s 50-day simple moving average is $44.74 and its two-hundred day simple moving average is $40.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.10. The firm had revenue of $18.98 billion during the quarter, compared to analyst estimates of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same quarter last year, the business posted $0.78 EPS. Research analysts anticipate that Pfizer Inc. will post 4.12 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend was Thursday, July 29th. Pfizer’s payout ratio is 70.27%.

Several equities research analysts have weighed in on the company. SVB Leerink restated a “hold” rating and set a $49.00 target price on shares of Pfizer in a research note on Tuesday. The Goldman Sachs Group set a $48.00 price target on shares of Pfizer in a report on Thursday, July 29th. Morgan Stanley upped their price target on shares of Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a report on Thursday, July 29th. Mizuho upped their price target on shares of Pfizer from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Friday, July 30th. Finally, Truist assumed coverage on Pfizer in a report on Tuesday, July 27th. They issued a “buy” rating and a $43.00 price objective for the company. Eleven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $42.77.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

See Also: Call Option

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.